NO170725C - Stereoselektiv fremgangsmaate for fremstilling av t-butylokskarbonylamino-gamma-laktoner egnet for fremstilling av renininhibitorer inneholdende 5-amino-2,5-disubstituerte-4-hydroksypentansyre-rester - Google Patents

Stereoselektiv fremgangsmaate for fremstilling av t-butylokskarbonylamino-gamma-laktoner egnet for fremstilling av renininhibitorer inneholdende 5-amino-2,5-disubstituerte-4-hydroksypentansyre-rester

Info

Publication number
NO170725C
NO170725C NO863202A NO863202A NO170725C NO 170725 C NO170725 C NO 170725C NO 863202 A NO863202 A NO 863202A NO 863202 A NO863202 A NO 863202A NO 170725 C NO170725 C NO 170725C
Authority
NO
Norway
Prior art keywords
sup
preparation
disubstituted
amino
laktons
Prior art date
Application number
NO863202A
Other languages
English (en)
Norwegian (no)
Other versions
NO863202D0 (no
NO170725B (no
NO863202L (no
Inventor
Jasjit Singh Bindra
Edward Fox Kleinman
Robert Louis Rosati
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO863202D0 publication Critical patent/NO863202D0/no
Publication of NO863202L publication Critical patent/NO863202L/no
Publication of NO170725B publication Critical patent/NO170725B/no
Publication of NO170725C publication Critical patent/NO170725C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/86—Renin inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
NO863202A 1985-08-09 1986-08-08 Stereoselektiv fremgangsmaate for fremstilling av t-butylokskarbonylamino-gamma-laktoner egnet for fremstilling av renininhibitorer inneholdende 5-amino-2,5-disubstituerte-4-hydroksypentansyre-rester NO170725C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76416885A 1985-08-09 1985-08-09
US06/858,324 US4729985A (en) 1985-08-09 1986-04-30 Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues

Publications (4)

Publication Number Publication Date
NO863202D0 NO863202D0 (no) 1986-08-08
NO863202L NO863202L (no) 1987-02-10
NO170725B NO170725B (no) 1992-08-17
NO170725C true NO170725C (no) 1992-11-25

Family

ID=27117410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO863202A NO170725C (no) 1985-08-09 1986-08-08 Stereoselektiv fremgangsmaate for fremstilling av t-butylokskarbonylamino-gamma-laktoner egnet for fremstilling av renininhibitorer inneholdende 5-amino-2,5-disubstituerte-4-hydroksypentansyre-rester

Country Status (22)

Country Link
US (1) US4729985A (fr)
EP (1) EP0212903B1 (fr)
JP (1) JPS6253952A (fr)
KR (1) KR890003603B1 (fr)
CN (1) CN86105870A (fr)
AT (1) ATE84046T1 (fr)
AU (1) AU576970B2 (fr)
CA (1) CA1294736C (fr)
DE (1) DE3687380T2 (fr)
DK (1) DK379186A (fr)
EG (1) EG17971A (fr)
ES (1) ES2000852A6 (fr)
FI (1) FI86192C (fr)
GR (1) GR862078B (fr)
HU (1) HU207101B (fr)
IE (1) IE58524B1 (fr)
IL (1) IL79626A0 (fr)
NO (1) NO170725C (fr)
NZ (1) NZ217127A (fr)
PH (1) PH24494A (fr)
PT (1) PT83172B (fr)
YU (1) YU45355B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727060A (en) * 1984-11-13 1988-02-23 Ciba-Geigy Corporation Novel 5-amino-4-hydroxyvaleryl derivatives
DE3538749A1 (de) * 1985-10-31 1987-05-07 Merck Patent Gmbh Peptide
EP0236734A3 (fr) * 1986-02-07 1988-05-11 Ciba-Geigy Ag Dérivés d'amino-5-hydroxy-4-valeryl substitués par des groupes contenant du soufre
DE3626130A1 (de) * 1986-08-01 1988-02-11 Merck Patent Gmbh Aminosaeurederivate
US4681972A (en) * 1986-09-16 1987-07-21 Warner-Lambert Company Separation of diastereomers
US4851387A (en) * 1986-10-14 1989-07-25 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4927565A (en) * 1986-12-19 1990-05-22 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentenoic acid derivatives and their use
US4758584A (en) * 1987-02-05 1988-07-19 Ciba-Geigy Corporation Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups
DE3888031T2 (de) * 1987-07-01 1994-06-09 Pfizer Homocyclostatin und Cyclostatin enthaltende Polypeptide als Antihypertensiva.
US4859654A (en) * 1987-07-01 1989-08-22 Pfizer Inc. Homocyclostatine and cyclostatine containing polypeptides as antihypertensive agents
EP0312158A3 (fr) * 1987-10-13 1990-07-25 Merck & Co. Inc. Tétrapeptides ayant des composantes d'amides d'acides aminés C-terminales, inhibiteurs de la rénine
GB8728561D0 (en) * 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
GB8728560D0 (en) * 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
ES2058489T3 (es) * 1988-01-26 1994-11-01 Sankyo Co Oligopeptidos con actividades inhibidoras de la renina, su preparacion y su uso.
AU632468B2 (en) * 1988-02-01 1993-01-07 Upjohn Company, The Renin inhibiting peptides with polar end groups
JPS6486550A (en) * 1988-08-19 1989-03-31 Seiko Epson Corp Complementary mos integrated circuit
US5436339A (en) * 1991-03-06 1995-07-25 Abbott Laboratories Process for the preparation of a substituted diaminoalcohol
US5238935A (en) * 1991-05-20 1993-08-24 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
US5124337A (en) * 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
TW217410B (fr) * 1992-04-01 1993-12-11 Ciba Geigy
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0702004A2 (fr) * 1994-09-15 1996-03-20 Ciba-Geigy Ag Dérivés d'amides d'acide 2,9-diamino- et 2-amino-2-carbamoyl-4-hydroxy-alcanoiques
EP0716077A1 (fr) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Amides d'acides oméga-amino alcanoiques et diamides alcanoiques ayant un substituant aromatique et leur application en tant qu'inhibiteurs de leur rénine
CA2191924A1 (fr) * 1995-12-05 1997-06-06 Kevin Felsenstein Derives de 5-amino-6-cyclohexyl-4-hydroxyhexanamide, inhibiteurs de la production de proteine .beta.-amyloide
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
DE60124080T2 (de) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
US8779198B2 (en) * 2009-08-11 2014-07-15 Novartis Ag Ring opening of lactones and lactams
CN105195868B (zh) * 2015-11-12 2018-05-15 上海电气核电设备有限公司 一种机器人焊接系统及其焊接方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163676A (en) * 1978-04-03 1979-08-07 Blue Cross Laboratories Ethanol-modified lecithin cookware spray composition
NO812612L (no) * 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
CA1258748A (fr) * 1981-10-08 1989-08-22 Daniel F. Veber Peptides inhibiteurs de la renine
US4478826A (en) * 1981-10-08 1984-10-23 Merck & Co., Inc. Renin inhibitory peptides
US4470971A (en) 1981-10-19 1984-09-11 Merck & Co., Inc. Renin inhibitory peptides having His13
US4397786A (en) 1981-11-23 1983-08-09 Merck & Co., Inc. Method of preparing statine and derivatives
CA1245217A (fr) * 1981-12-10 1988-11-22 Joshua S. Boger Peptides inhibiteurs de la renine
WO1984003044A1 (fr) * 1983-02-07 1984-08-16 Ferring Ab Inhibiteurs enzymatiques
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
DK110285A (da) * 1984-03-12 1985-09-13 Pfizer Polypeptider og polypeptidderivater indeholdende statin eller derivater deraf og farmaceutiske praeparater
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
DK356085A (da) * 1984-08-06 1986-02-07 Upjohn Co Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
DE3512128A1 (de) * 1985-04-03 1986-10-09 Merck Patent Gmbh, 6100 Darmstadt Peptide

Also Published As

Publication number Publication date
KR890003603B1 (ko) 1989-09-27
GR862078B (en) 1986-12-24
EP0212903A3 (en) 1989-11-15
DE3687380T2 (de) 1993-04-29
ATE84046T1 (de) 1993-01-15
YU45355B (en) 1992-05-28
EP0212903A2 (fr) 1987-03-04
IE862143L (en) 1987-02-09
DK379186A (da) 1987-04-01
PT83172B (pt) 1989-03-30
FI863250A0 (fi) 1986-08-08
EG17971A (en) 1991-11-30
FI86192C (fi) 1992-07-27
CN86105870A (zh) 1987-03-11
AU576970B2 (en) 1988-09-08
YU142286A (en) 1988-10-31
US4729985A (en) 1988-03-08
JPH0543697B2 (fr) 1993-07-02
NO863202D0 (no) 1986-08-08
NO170725B (no) 1992-08-17
EP0212903B1 (fr) 1992-12-30
NZ217127A (en) 1989-11-28
PH24494A (en) 1990-07-18
PT83172A (en) 1986-09-01
AU6102186A (en) 1987-02-12
KR870002164A (ko) 1987-03-30
ES2000852A6 (es) 1988-03-16
IL79626A0 (en) 1986-11-30
HU207101B (en) 1993-03-01
DE3687380D1 (de) 1993-02-11
FI863250A (fi) 1987-02-10
DK379186D0 (da) 1986-08-08
CA1294736C (fr) 1992-01-21
JPS6253952A (ja) 1987-03-09
IE58524B1 (en) 1993-10-06
FI86192B (fi) 1992-04-15
HUT41419A (en) 1987-04-28
NO863202L (no) 1987-02-10

Similar Documents

Publication Publication Date Title
NO170725C (no) Stereoselektiv fremgangsmaate for fremstilling av t-butylokskarbonylamino-gamma-laktoner egnet for fremstilling av renininhibitorer inneholdende 5-amino-2,5-disubstituerte-4-hydroksypentansyre-rester
MA18664A1 (fr) Derives d'amino-acides utiles comme agents contre l'hypertension
DE69609051T2 (de) Tricyclische substituierte hexahydrobenz[e]isoindol alpha-1-adrenergische antagonisten
DK0805812T3 (da) Bicyklisk substitueret hexahydrobenz[e]isoindol som alfa-1-adrenerge antagonister
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
EA200100661A1 (ru) Способ получения производных 2-азадигидроксибицикло [2.2.1] гептана
KR850006941A (ko) 데스-프로린 바조프레신 길항제의 제조방법
FI871637A0 (fi) Foerfarande foer framstaellning av 1,5-benzotiazepinderivat.
ATE36854T1 (de) Tetrahydrothienopyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
AR004727A1 (es) El uso de un compuesto para la transfeccion de celulas y una composicion
KR910009663A (ko) 피리딘유도체, 이들을 함유하는 약리학적 조성물 및 이들의 제조방법
DE69705640T2 (de) Verfahren zur herstellung von heteroaryl-phenylalaninen
ATE80400T1 (de) Tetrapeptid-hemmstoff zum eintritt in den kreislauf von hemopoietischen stammzellen, verfahren zu deren herstellung und deren anwendungen.
DE3571031D1 (en) Antihypertensive 1,2-benzisothiazole piperidines, a method for synthesizing the same and their use as medicaments
ATE69810T1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeure und deren verwendung als collagenaseinhibitoren.